New EQ-PSO Instrument Developed To Evaluate Psoriasis Patients

Published Nov 20, 2013
Oxford, United Kingdom - Psoriasis is a chronic autoimmune condition of the skin that affects approximately 125 million people around the world. In addition to causing pain, itch and discomfort, psoriasis can leave patients feeling self-conscious about what others might be thinking about their disease, severely impacting their self-image, relationships and quality of life more generally. Previous research has highlighted that the EQ-5D – a widely used generic measure for the assessment of health status – may be insensitive in some disease states, including psoriasis. The development of disease-specific “bolt-on” modules has been suggested as one potential solution to problems with content validity. Researchers at Eli Lilly and Company in collaboration with Oxford Outcomes, explored the feasibility of developing and valuing a disease-specific version of the EQ-5D for use in psoriasis. A review of published literature, discussion with a clinical expert and exploratory interviews with patients were all undertaken to identify potential additional dimensions for a psoriasis-specific version of the EQ-5D. The resulting instrument, the EQ-PSO, assesses “skin irritation” and “self-confidence” in addition to the existing five dimensions. The new EQ-PSO instrument may yield greater responsiveness to changes in health status in patients with psoriasis, allowing for more accurate measurements of the burden of psoriasis and the value of treatments for the condition. “The development of a ‘bolt-on’ version of the EQ-5D instrument is an important step in the field of valuation. We hope the EQ-PSO will be seen as an essential addition to the set of outcome measures suitable for use in psoriasis, allowing for a more accurate evaluation of health status for psoriasis patients in the near future,” said Andrew Lloyd, vice president of Patient Reported Outcomes at Oxford Outcomes.  The full study, “Development of a Disease-Specific Version of the EQ-5D-5L for Use in Patients Suffering from Psoriasis: Lessons Learned from a Feasibility Study in the UK,” is published in Value in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information:

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now